Nov. 20, 2024 — Wings may be the obvious choice when studying the connection between dinosaurs and birds, but a pair of paleontologists prefer drumsticks. That part of the leg, they say, is ...

Ruxolitinib cream for vitiligo showed 60% of patients maintained benefits post-treatment, with potential for skin repigmentation upon reinitiation. JNJ-2113 demonstrated significant efficacy in ...

Dec. 18, 2024 — Until now, scientists have been unable to determine how metformin, a Type 2 diabetes medication that lowers blood sugar, works. A study provided direct evidence in mice that it ...

The revision follows AnaptysBio's recent Phase 2b trial failure of ANB032 in atopic dermatitis (AD), which led to its removal from the sum-of-the-parts (SOTP) valuation of the company. The stock, ...

The failure of ANB032 in Phase 2B for atopic dermatitis has shifted focus to rosnilimab, which faces significant competition and uncertain prospects. Rosnilimab's upcoming Phase 2B results for ...

and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

It was a busy week in the biotech sector with lots of regulatory and pipeline updates. Among bigwigs, Gilead Sciences, Inc.

The revision follows AnaptysBio's recent Phase 2b trial failure of ANB032 in atopic dermatitis (AD), which led to its removal from the sum-of-the-parts (SOTP) valuation of the company. The stock ...